磷酸二酯酶-5抑制剂与心脏:复合心脏保护作用?
综述探讨PDE5抑制剂在心力衰竭和心肌梗死中的心脏保护证据。细胞与动物模型显示其改善收缩功能、逆转左室肥厚、缩小梗死面积并抑制缺血诱导的室性心律失常,机制涉及cGMP-PKG通路。临床试验中PDE5抑制剂改善收缩性心衰症状与心室功能,流行病学数据提示高心血管风险使用者心血管事件与死亡率降低。
要点
- PDE5抑制剂通过cGMP-PKG通路发挥多重心脏保护作用,包括直接心肌作用。
- 收缩性心衰临床试验中改善症状与心室功能,高心血管风险人群流行病学示事件与死亡减少。
- 未来临床试验需结合机制设计以识别最大获益患者亚组。
核心结论
- PDE5抑制剂通过多种心脏保护机制发挥作用,包括独立于血管的直接心肌作用。
- 未来临床试验应结合这些机制设计,以识别从这类新型心脏保护剂中获益最大的患者亚组。
研究设计与样本
- 综述整合细胞研究、动物模型、临床试验与流行病学数据,聚焦基础科学向临床研究的转化。
主要发现
- 细胞与动物模型显示PDE5抑制剂改善收缩性心衰的收缩功能、逆转左室肥厚、缩小心肌梗死面积并抑制缺血诱导的室性心律失常。
- 临床试验中PDE5抑制剂改善收缩性心衰患者的症状与心室功能。
- 累积流行病学数据提示高心血管风险PDE5抑制剂使用者心血管事件与死亡率降低。
临床怎么用
- 关注PDE5抑制剂在收缩性心衰和高心血管风险人群中的潜在心脏保护获益。
- 未来试验设计需结合cGMP-PKG机制以筛选最大获益患者亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel cardioprotective agents are needed in both heart failure (HF) and myocardial infarction. Increasing evidence from cellular studies and animal models indicate protective effects of phosphodiesterase-5 (PDE5) inhibitors, drugs usually reserved as treatments of erectile dysfunction and pulmonary arterial hypertension. PDE5 inhibitors have been shown to improve contractile function in systolic HF, regress left ventricular hypertrophy, reduce myocardial infarct size and suppress ischaemia-induced ventricular arrhythmias. Underpinning these actions are complex but increasingly understood cellular mechanisms involving the cyclic GMP activation of protein kinase-G in both cardiac myocytes and the vasculature. In clinical trials, PDE5 inhibitors improve symptoms and ventricular function in systolic HF, and accumulating epidemiological data indicate a reduction in cardiovascular events and mortality in PDE5 inhibitor users at high cardiovascular risk. Here, we focus on the translation of underpinning basic science to clinical studies and report that PDE5 inhibitors act through a number of cardioprotective mechanisms, including a direct myocardial action independent of the vasculature. We conclude that future clinical trials should be designed with these mechanisms in mind to identify patient subsets that derive greatest treatment benefit from these novel cardioprotective agents.
引用
- Hutchings DC, Anderson SG, Caldwell JL, et al. Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart. 2018. PMID: 29519873. doi:10.1136/heartjnl-2017-312865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。